Waldencast plc (WALD) Form 6-K — Jun 15, 2026
Waldencast plc announced that its subsidiary Obagi Medical received FDA approval for Obagi saypha ChIQ, an injectable hyaluronic acid gel used for cheek augmentation and correction of midface contour deficiencies. The product utilizes proprietary MACRO Core Technology and expands Obagi's portfolio in the growing U.S. dermal filler market, building on the recent launch of saypha MagIQ. Separately, Waldencast's subsidiaries entered into a Second Amendment to the Credit Agreement with lenders, led by Lumina Fund II GP Ltd., to postpone the deadline for issuing warrants to Tranche B Lenders from July 1, 2026, to November 17, 2026.
Key figures
- Warrants per loan
- 1,000 ordinary shares per $1,000 principal amount
- Tranche b warrant deadline new
- November 17, 2026
- Tranche b warrant deadline original
- July 1, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.